UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
21.35
+0.83 (4.04%)
Feb 6, 2026, 4:00 PM EST - Market closed
UroGen Pharma Revenue
UroGen Pharma had revenue of $27.48M in the quarter ending September 30, 2025, with 9.04% growth. This brings the company's revenue in the last twelve months to $96.52M, up 8.00% year-over-year. In the year 2024, UroGen Pharma had annual revenue of $90.40M with 9.29% growth.
Revenue (ttm)
$96.52M
Revenue Growth
+8.00%
P/S Ratio
10.52
Revenue / Employee
$336,293
Employees
287
Market Cap
999.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 90.40M | 7.69M | 9.29% |
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | 18.00K | -1.11M | -98.40% |
| Dec 31, 2018 | 1.13M | -7.03M | -86.17% |
| Dec 31, 2017 | 8.16M | -9.37M | -53.46% |
| Dec 31, 2016 | 17.53M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Iovance Biotherapeutics | 250.43M |
| Geron | 183.40M |
| ARS Pharmaceuticals | 142.77M |
| CytomX Therapeutics | 113.63M |
| Theravance Biopharma | 80.33M |
| EyePoint | 42.34M |
| AbCellera Biologics | 35.33M |
URGN News
- 2 days ago - UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit - GlobeNewsWire
- 4 weeks ago - Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy - GlobeNewsWire
- 2 months ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates - Seeking Alpha
- 2 months ago - UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum - GlobeNewsWire
- 3 months ago - UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial - GlobeNewsWire